Insights
Search Results
Client Highlights
3.15.22
Wilson Sonsini Advises Nalu Medical on $104 Million Equity Financing
On February 17, 2022, Nalu Medical, Inc., a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced a $104 million equity financing. The round was led by new investors MVM Partners and Gilde Healthcare. New investors Pura Vida Investments and Aperture Venture Partners, as well as existing investors Advent Life Sciences, Decheng Capital, Endeavour Vision, and Longitude Capital, also participated in the round. The proceeds from this financing are intended to be used for scaling commercial operations to accelerate growth, continued expansion of clinical evidence, and continuing product development, in addition to other general corporate purposes. Wilson Sonsini Goodrich & Rosati advised Nalu Medical on the transaction.
Newsletters
6.14.21
The Life Sciences Report – June 2021
In this issue, we feature articles on managing IP development and capture at growing medtech start-ups, life sciences venture financings in which firm clients participated during 2020, the U.S.-Japan Healthcare Connection's virtual conference on the coming revolution in healthcare, and the Biden administration's signing of two bipartisan bills that aim to promote drug competition and reduce prescription drug prices, as well as a summary of select recent life sciences client highlights.
Client Highlights
6.03.21
Wilson Sonsini Advises Emboline on $55 Million Series D Funding to Launch Emboliner™
On May 25, 2021, Emboline, Inc., a privately-held medical device company focused on reducing stroke and other damage caused by embolic debris released during transcatheter heart procedures, announced the closing of its Series D funding of over $55 million. Wilson Sonsini Goodrich & Rosati represented Emboline in the transaction.
Client Highlights
3.17.21
Wilson Sonsini Advises Riva Health on $15.5 Million Fundraise and Launch
On March 17, 2021, Riva Health, a new mobile cardiology app, announced $15.5 million in funding led by Menlo Ventures. UCHealth and University of Colorado Innovation Fund also participated in the round, as well as leading Chicago healthcare investors Brandon Cruz of GoHealth and Larry Gies of Madison Industries. This investment follows on the heels of a previous round led last year by Menlo Ventures, alongside True Ventures. Riva is led by CEO Dag Kittlaus, former co-founder of both Siri and Viv, and Tuhin Sinha, Ph.D. and co-founder of one of the largest cardiovascular research studies in the world, Health eHeart. Wilson Sonsini represented Riva Health in the transaction.
Client Highlights
2.26.21
Wilson Sonsini Advises Simplify Medical in Its Acquisition by NuVasive
On February 24, 2021, NuVasive, Inc., the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced that it has acquired Simplify Medical, a privately held company and developer of the Simplify® Cervical Artificial Disc (Simplify Disc) for cervical total disc replacement (cTDR). Wilson Sonsini Goodrich & Rosati represented Simplify Medical in the transaction.
Press Releases
12.07.20
Wilson Sonsini Elects 15 New Partners
Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, today announced that the firm has elected 15 new partners from its attorney ranks. The promotions will be effective February 1, 2021.
Client Highlights
11.19.20
Wilson Sonsini Advises MedAvail in its Business Combination with MYOS RENS Technology
On November 18, 2020, MedAvail, Inc., a healthcare technology company that embeds pharmacy services directly into clinics and other points of care, announced the completion of its previously announced business combination with MYOS RENS Technology, Inc., an advanced nutrition company focused on improving muscle health. Wilson Sonsini advised MedAvail in the transaction.
Client Highlights
9.18.18
IRIDEX Closes Follow-On Offering
On September 18, 2018, IRIDEX, an ophthalmology company focused on the development and commercialization of novel products and procedures used to treat glaucoma and retinal diseases, closed its underwritten public offering of 1,666,667 shares of its common stock at a price to the public of $6.00 per share. In addition, the company granted the underwriters a 30-day option to purchase up to 250,000 additional shares of its common stock in the public offering and the option was exercised prior to closing. Wilson Sonsini Goodrich & Rosati represented IRIDEX in the offering.